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AT A GLANCE COMMENTARY 
Scientific Knowledge on the Subject 
Lung function and chronic obstructive pulmonary disease (COPD) are heritable traits. 
Prior genome-wide association studies (GWAS) of lung function have identified 
numerous genetic variants associated with COPD risk; however, much of the individual 
variance in lung function remains unexplained. Furthermore, most of these studies have 
been limited to participants of European ancestry. Including multi-ethnic populations in 
GWAS research may identify novel variants that contribute to the etiology of lung 
function. 
What this Study Adds to the Field 
This study, the largest GWAS of lung function and COPD to exclusively include 
Hispanic/Latino participants, identified eight novel signals of which three replicated in 
independent populations. A novel locus for FEV1 (rs4791658; ZSWIM7) replicated in a 
cohort of European ancestry. A locus for FEV1/FVC (rs145174011; HAL); in a previously 
identified region for FEV1/FVC in individuals of European ancestry and for percent 
emphysema in a Hispanic population remained independent in conditional analyses but 
did not replicate. Admixture mapping identified a novel region associated with 
Amerindian ancestry and FEV1 which included a candidate variant (rs4133185) in the 
AGMO gene that replicated. Additionally, we identified a SNP (rs7709630) for COPD, 
which replicated in individuals of European ancestry. Several loci previously identified in 
European samples were also associated with lung function traits among Hispanic/Latino 
participants in HCHS/SOL at the genome-wide significance level. These results 
emphasize the importance of including admixed populations when performing genetic 
studies to identify variants that may contribute to the genetic etiology of pulmonary 
function and COPD.   
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ABSTRACT  
Rationale:  Lung function and chronic obstructive pulmonary disease (COPD) are 
heritable traits. Genome-wide association studies (GWAS) have identified numerous 
pulmonary function and COPD loci, primarily in cohorts of European ancestry. 
Objectives: Perform a GWAS of COPD-phenotypes in Hispanic/Latino populations to 
identify loci not previously detected in European populations.  
Methods: GWAS of lung function and COPD in Hispanic/Latino participants from a 
population-based cohort. We performed replication studies of novel loci in independent 
studies. 
Measurements and Main Results: Among 11,822 Hispanic/Latino participants, we 
identified eight novel signals; three replicated in independent populations of European 
Ancestry. A novel locus for forced expiratory volume in one second (FEV1) in ZSWIM7 
(rs4791658; p=4.99×10-9) replicated. A rare variant (MAF=0.002) in HAL (rs145174011) 
was associated with FEV1 to forced vital capacity (FEV1/FVC) (p=9.59×10-9) in a region 
previously identified for COPD-related phenotypes; it remained significant in conditional 
analyses but did not replicate. Admixture mapping identified a novel region, with a 
variant in AGMO (rs41331850), associated with Amerindian ancestry and FEV1, which 
replicated. A novel locus for FEV1 identified among ever smokers (rs291231; 
p=1.92×10-8) approached statistical significance for replication in admixed populations 
of African ancestry and a novel SNP for COPD in PDZD2 (rs7709630; p=1.56×10-8) 
regionally replicated. Additionally, loci previously identified for lung function in European 
samples were associated in Hispanic/Latino participants in HCHS/SOL at the genome-
wide significance level.  
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Conclusions: We identified novel signals for lung function and COPD in a 
Hispanic/Latino cohort. Including admixed populations when performing genetic studies 
may identify variants contributing to genetic etiologies of COPD.  
 
Word Count: 250 
Key Words: Hispanic/Latino, genome-wide association study, single nucleotide 
polymorphisms, lung function, airflow limitation, chronic obstructive pulmonary disease  
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INTRODUCTION  
The Hispanic/Latino population is the largest and fastest-growing minority population in 
the United States (U.S.), accounting for 17% of the U.S. population currently and an 
estimated 33% by 2060(1). The Hispanic/Latino population in the U.S. is genetically 
diverse, with a mixture of European, African and Amerindian genetic ancestries(2-4).   
 Chronic obstructive pulmonary disease (COPD), characterized by persistent 
airflow obstruction(5, 6), is the third-leading cause of death in the U.S.(7). The 
prevalence of COPD in some Hispanic groups is lower than in non-Hispanic whites and 
African-Americans in the U.S.(8-10).  In the Hispanic Community Health Study/Study of 
Latinos (HCHS/SOL), the largest and best characterized cohort of Hispanics/Latinos in 
the US, the prevalence of COPD varied substantially by Hispanic/Latino heritage with 
Puerto Ricans and Cubans having a much higher prevalence of COPD than other 
Hispanic/Latino groups(10).  This difference in HCHS/SOL was explained by smoking 
and asthma history; however, other investigators have noted that Hispanic ethnicity is 
inversely associated with COPD-phenotypes compared to whites(11, 12) and have 
hypothesized that genetic differences may lower risk of COPD in some Hispanic 
groups(11, 13).   
Examination of genetic risk among non-European populations may reveal novel 
variants that yield new pathways to treatments, such as PCSK9(14). We are aware of 
only two genome-wide association studies (GWAS) of lung function or COPD-related 
phenotypes that analyzed Hispanics separately(13, 15). One identified a novel variant 
near MAN2B1 that was associated with percent emphysema on computed tomography 
(CT)(16) and the other identified two loci that approached genome wide statistical 
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significance for COPD(13).  This literature contrasts with that among persons of 
European ancestry, in whom GWAS have identified multiple loci in genes for lung 
function and COPD(17-31) 
 To improve our current understanding of the genetic architecture of lung function-
related traits in Hispanics/Latinos, we performed a meta-analysis for FEV1, FEV1/FVC, 
airflow limitation and COPD among six Hispanic/Latino groups in the HCHS/SOL 
cohort(10, 32).  Findings were replicated in European, Hispanic and African populations. 
Some of the results have been previously reported in abstract form(33). 
 
METHODS  
Study Sample 
HCHS/SOL is a community-based cohort study of 16,415 self-identified Hispanic/Latino 
persons aged 18-74 years recruited from four U.S. communities. The study design, 
cohort recruitment(10, 32), and baseline clinical examination(34) have been previously 
described. Institutional Review Boards at each field center approved study protocols 
and written informed consent was obtained from all participants.  
 For genetic analyses, HCHS/SOL participants were classified in six genetic 
analysis groups: Central American, Cuban, Dominican, Mexican, Puerto Rican, and 
South American. The genetic ancestry structure of these groups, including principal 
components (PCs) plots for all individuals, have been previously reported(35). 
Henceforward we will refer to the six genetic analysis groups as Hispanic/Latino 
ancestry groups.  
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Exclusion criteria were lack of valid spirometric or genetic data, missing 
covariates, near exclusive Asian ancestry and participants who were not classified in 
the Hispanic/Latino ancestry groups.  Details are provided in the online supplement. 
 
Phenotypic and Outcome Measures 
Spirometry was conducted in accordance with American Thoracic Society/European 
Respiratory Society guidelines(36) using a dry rolling sealed spirometer as previously 
described(10). Participants with pre-bronchodilator FEV1/FVC ratios less than 70% or 
the lower limit of normal were selected for post-bronchodilator spirometry, the former 
defined by NHANES reference equations(37) since those from HCHS/SOL(38) were not 
available during data collection.  
Airflow limitation was defined as a pre-bronchodilator FEV1/FVC ratio < 70% and 
COPD as a post-bronchodilator FEV1/FVC ratio < 70%(5). Controls had normal lung 
function defined as a pre-bronchodilator FEV1/FVC ratio > 70% and FVC > 80 percent 
predicted.  
 
Genotyping, Quality Control and Imputation 
Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 
15041502 B3 array.  We applied standard quality-assurance and quality-control 
methods(39) as previously described(35). Genome-wide imputation was carried out with 
the full, cosmopolitan 1000 Genomes Project phase 1 reference panel(40); associations 
for novel loci were confirmed with 1000 Genome phase 3 imputation panel. Details are 
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provided in the online supplement.   
 
Statistical Analyses 
See the online supplement for details.  
Quantitative Lung Function Analyses 
Analyses of FEV1 and FEV1/FVC ratio employed linear mixed models, stratified by 
Hispanic/Latino ancestry group, and adjusted for age, age2, sex, height, height2, study 
center, smoking status, pack-years, sampling weights, and the first 5 PCs, as fixed 
effects.  We used random effects for genetic relatedness (kinship), and household and 
community (block unit) to account for environmental correlation. Results from each 
Hispanic/Latino ancestry group were then meta-analyzed using the MetaCor 
method(41). Genome-wide significance threshold was defined as p<5x10-8, the 
Bonferroni adjustment for 1 million independent tests (42). A priori, we planned 
additional meta-analyses stratified by never vs ever smoking.  
 
Analyses for Airflow Limitation and COPD 
We analyzed airflow limitation and COPD in pooled analyses implementing the GMMAT 
software(43) to fit a logistic mixed model adjusting for age, sex, study center, smoking 
status, pack-years, sampling weights, the first 5 PCs and Hispanic/Latino ancestry 
groups, as fixed effects and with random effects for kinship and block unit. Participants 
younger than 45 years were excluded.  
 
Admixture Mapping and Analyses 
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Local ancestry estimates were previously inferred in the HCHS/SOL(44).  A genome-
wide admixture mapping scan was performed using a linear mixed model, as described 
above, testing European, African, and Amerindian ancestries at each available local 
ancestry interval (LAI).  Statistical significance  for  admixture mapping was set at 
p<5.68x10-5 based on previous simulation results for HCHS/SOL(45). After discovering 
a genome-wide significant LAI association (at the admixture mapping level), we 
identified a candidate variant and performed conditional admixture mapping 
analysis(46).  
 
Replication of Lung Function SNPs  
We pursued replication of novel loci associated with FEV1 and FEV1/FVC in populations 
with Hispanics(13, 47-51), African-American(47, 48), and European representation(17). 
We performed a look-up in each individual study then meta-analyzed across studies. 
For airflow limitation and COPD, we performed regional replication in publically 
available GWAS results of airflow obstruction in participants of European ancestry(23). 
For admixture mapping signals, we performed a look-up in the UK Biobank results for 
individuals of European ancestry 
(https://sites.google.com/broadinstitute.org/ukbbgwasresults).  
  
Generalization analyses of previously reported SNPs 
We looked-up previously reported SNPs, their effects, standard errors and p-value in 
HCHS/SOL(52).  
 
8 
 
RESULTS  
The mean age of the 11,822 HCHS/SOL participants with valid lung function and 
genetic data was 46±14 years.  Thirty-nine percent had ever smoked cigarettes with 
median pack-years of 7.5. The COPD analysis included 363 and 5,253 individuals with 
and without COPD, respectively. Characteristics of the participants are shown in table 
1.  Manhattan and Quantile-Quantile (Q-Q) plots for FEV1, FEV1/FVC, airflow limitation 
and COPD are shown in figures E1, E2, E3 and E4.  Genomic inflation factors ranged 
from 1.020–1.026 in quantitative lung function analyses and 0.988–1.011 in analyses of 
COPD.  
 
GWAS of Lung Function across all Hispanic/Latino ancestry groups 
Across all Hispanic/Latino ancestry groups, seven signals achieved genome-wide 
statistical significance, of which two were novel for lung function (table 2). The lead 
novel SNP, rs4791658, in the locus associated with FEV1 (figure 1a) was an intron 
variant in the gene ZSWIM7 on chromosome 17 (Beta=33.4, p=4.99×10-9). Its minor 
allele frequency (MAF) ranges from 0.39–0.49 across Hispanic/Latino ancestry groups 
(figure 1b).  SNP, rs4791658 neared genome-wide significance for FEV1 among ever 
smokers (Beta=46.8, p=1.53×10-6).  Effect size and p-values for rs4791658 across all 
lung function and COPD-related traits are shown in Table E1. 
The lead novel SNP, rs145174011, in the locus associated with FEV1/FVC 
(figure 1c) was an intronic variant in the gene HAL on chromosome 12 (Beta=4.86, 
p=9.59×10-9). The SNP is rare with a MAF that ranges from 0.001–0.008 across 
Hispanic/Latino ancestry groups (figure 1d). The minor allele does not exhibit an outlier 
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effect (figure E5).  Sensitivity analysis using rank-normalized residuals is shown in 
supplement. This locus is near the gene CCDC38, which was previously identified for 
FEV1/FVC in individuals of European Ancestry (17) and the gene SNRPF, which was 
previously identified for percent emphysema on CT in racially/ethnically diverse 
participants (16). In conditional analysis adjusting for rs1036429 (CCDC38) and 
rs7957346 (SNRPF) in HCHS/SOL, rs145174011 (HAL SNP) remained associated with 
FEV1/FVC (Beta=4.92 p=6.4×10-9), suggesting its association with FEV1/FVC is 
independent of previously identified variants.  The findings for rs145174011 among ever 
and never smokers are concordant and trended towards significance (table E1). 
Regional association plots and forest plots of previously reported genome wide 
significant associations for FEV1 and FEV1/FVC meta-analyzed across all 
Hispanic/Latino ancestry groups are shown in figure E6.  
 
Stratification by Smoking Status 
In the meta-analysis across all Hispanic/Latino ancestry groups stratified by smoking 
status, we identified one novel locus among ever smokers for FEV1 and one novel locus 
among never smokers for FEV1/FVC (table 3). The lead variant in the locus associated 
with FEV1 in ever smokers was an Indel variant (p=1.66×10-8) on chromosome 11. The 
top SNP, rs291231 (Beta=57.28, p=1.92×10-8), in this locus has a MAF that ranges from 
0.28 – 0.42 across Hispanic/Latino ancestry groups. This SNP lies between the genes 
EED and CCDC81 (figure 2a and 2b). The SNP-by-pack-years interaction trended 
towards significance (p-interaction=0.06) and the genotype effect became greater at 
higher pack-years (figure E7). 
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The top SNP (rs7228593) in the locus associated with FEV1/FVC in never 
smokers (Beta=1.34, p=3.47×10-8) is located between the genes SMIM21 and 
LCOC339298 (figure 2c) on chromosome 18. The findings in never smokers for airflow 
limitation (OR=0.46, p=2.63×10-4) and COPD (OR=0.36, p=0.005) were directionally 
concordant and trended towards significance (table E1). Its MAF varies significantly 
across different Hispanic/Latino ancestry groups (figure 2d) with the highest in 
participants from the Dominican ancestry group (MAF=0.16) and lowest in Mexican 
ancestry group (MAF=0.02). Forest plots and regional association plot of remaining 
genome-wide significant associations for FEV1 and FEV1/FVC stratified by smoking 
status are shown in figure E8.  
 
GWAS of COPD  
We identified two previously unreported SNPs for COPD (table E2 and figure E9). SNP 
rs7709630 is an intron in the PDZD2 gene on chromosome 5 (p=1.56×10-8; MAF=0.11) 
and SNP rs2286351 is a noncoding transcript variant in CDRT15P1 on chromosome 17 
(p=1.97×10-8, MAF=0.09). Lung function association analyses of these COPD SNPs are 
reported in table E3.  
 
Admixture Mapping: 
Manhattan plots from admixture mapping analyses for FEV1, and FEV1/FVC testing 
Amerindian, African, and European ancestry counts individually in LAIs are shown in 
figures E10 and E11. We identified one novel significant local ancestry association 
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region of Amerindian ancestry for FEV1 (figure E10a) on chromosome 7 (Beta =-37.51, 
p=2.86x10-6). There were no significant associations in the European versus others or 
African versus others analyses.  
We identified a candidate variant (rs4133185) within this novel LAI region (Beta = 
-31.44, p= 7.43x10-7; table E4 and figure 3) with considerable differences in ancestry-
specific allele frequencies (figure 4). The lead SNP, rs4133185, in this candidate 
variant was an intron variant in the gene AGMO.  The admixture mapping signal is less 
significant after conditional analyses adjusting for rs4133185 (table E5, figures 4 and 
E12).   
 
Replication 
Characteristics of the participants in the replication cohorts are shown in table E4. Of 
the two novel loci identified for lung function, only the FEV1 locus on chromosome 17 
successfully replicated (replication p=3.37x10-5; adjusted threshold for statistical 
significance was p<9.2x10-4) but only in the SpiroMeta consortium look-up 
(n=94,612)(17).  The candidate variant (rs4133185), identified through admixture 
mapping, associated with Amerindian ancestry and FEV1 replicated in UK Biobank 
(Beta = -8.3, p=0.004). SNP rs291239, a genotyped SNP in the novel locus on 
chromosome 11 identified for FEV1 among ever smokers, approached statistical 
significance for replication in the meta-analysis across all cohorts with admixed 
populations of African ancestry (replication p=0.007); however, the direction of effect 
was discordant in the individual replication cohorts (table E7).   
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The novel SNP (rs7709630; PDZD2) associated with COPD regionally replicated 
in publically available results from the SpiroMeta-CHARGE GWAS meta-analysis of 
airflow obstruction among participants of European ancestry(23). The smallest p-value 
in the replication region was for rs409839 (p=8.9x10-4) and the adjusted threshold for 
statistical significance was p< 4.2x10-3. The other loci were not successfully replicated. 
 
Generalization Analyses of Previously Identified Lung Function Loci 
Using the FDR adjusted look-up threshold, several of the previously reported SNPs for 
FEV1, FEV1/FVC and COPD identified in European populations were generalized to 
Hispanic/Latino populations (tables E8, E9, E10 and Figure E13). See online 
supplement for details. 
 
DISCUSSION 
In this GWAS of 11,822 Hispanic/Latino HCHS/SOL participants, we identified eight 
novel signals, of which three replicated in independent cohorts of European ancestry.  
Three novel signals were associated with lung function. A novel locus in ZSWIM7 
(rs4791658) was associated with FEV1 replicated and a rare variant in HAL 
(rs145174011) was associated with FEV1/FVC did not replicate; it is in a previously 
identified region but remained significant in conditional analyses, suggesting an 
independent effect. Admixture mapping identified a novel LAI region, with a candidate 
variant in the AGMO gene (rs4133185), associated with Amerindian ancestry and FEV1, 
which replicated. In smoking stratified analyses, a novel locus (rs291231) associated 
with FEV1 among 4,595 ever smokers approached statistical significance for replication 
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in cohorts with admixed populations of African ancestry and a novel SNP for COPD in 
PDZD2 (rs7709630) regionally replicated in individuals of European ancestry. In 
addition, we confirmed loci previously identified in European samples [KCNE2(17) and 
GPR126(27) ] for FEV1/FVC in this Hispanic/Latino sample.   
Several SNPs in ZSWIM7 were associated with FEV1 at genome-wide 
significance and replicated in independent cohorts of European ancestry.  ZSWIM7 
mutations were associated colorectal adenomatous polyposis(53) and in a GWAS of 
SNP-by-smoking interaction, ZSWIM7 neared significance for systolic blood 
pressure(54). ZSWIM7 is a highly conserved eukaryotic regulator of homologous 
recombination and plays an important role in error-free DNA repair processes for DNA 
double-strand breaks (DSBs)(55-57). Unrepaired DSBs trigger cell senescence, 
apoptosis, and pro-inflammatory responses, all of which are established mechanisms in 
the pathogenesis of COPD(58-60). Oxidative stress and cigarette smoke cause 
DSBs(61, 62) and DSBs have been implicated in the pathogenesis of COPD(62). 
Furthermore, COPD patients have a greater number of unrepaired DSBs which are 
associated with a higher expression of markers for senescence, apoptosis, and pro-
inflammatory phenotypes compared to asymptomatic smokers and nonsmokers(62). In 
our study, the effect size of ZSWIM7 for FEV1 was of greater magnitude among ever 
smokers which is consistent with known effects of cigarette smoke causing DSBs.  
Thus, ZSWIM7 through its regulation of homologous recombination and role in error-
free DNA repair processes for DSBs is relevant to the pathogenesis of COPD.  
 A rare variant in HAL (rs145174011) was associated with FEV1/FVC among all 
participants.  The minor allele was associated with decreases in FEV1/FVC of 4.9% and 
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6.3% (all participants and ever smokers, respectively), and with decreases in FEV1 of 
100 mL and 173 mL (all participants and ever smokers, respectively). It is possible that 
this variant was not successfully replicated due to lack of power, given that it is a rare 
variant in African and Hispanic populations and is not polymorphic in European 
populations(63).  
The HAL SNP (rs145174011) is near two previously identified loci for pulmonary 
traits (CCDC38 and SNRPF). CCDC38 has been associated with FEV1/FVC in 
European ancestry individuals(17), and SNRPF has been associated with percent 
emphysema on CT in racially/ethnically diverse participants in the Multi-Ethnic Study of 
Atherosclerosis (MESA) Lung Study (16). In the MESA Lung Study, linkage 
disequilibrium (LD) between SNRPF and CCDC38 accounted for much of the effect 
seen in Whites, and less so in African Americans and Chinese; however, the observed 
effect of SNRF on percent emphysema on CT in Hispanics appeared to be independent 
from CCDC38(16).  In our study, the association of SNP rs145174011 (HAL locus) with 
FEV1/FVC was maintained in analyses conditioning on previously reported loci.  
Collectively, these data suggest there are three independent loci associated with 
COPD-related phenotypes in this region.  
Although the HAL locus contained numerous SNPs, they were all imputed rare 
variants and did not replicate; therefore, further investigation, such as whole-genome 
sequencing of this region and functional studies, is required to refine these loci, confirm 
association, and understand their biological implications for COPD. 
The HAL gene encodes the enzyme histidine ammonia-lyase(64, 65) - the first 
step in histidine catabolism(66). Low levels of histidine have been associated with 
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increased inflammation and oxidative stress(67)(68) and decreased concentrations of 
histidine were associated with advanced COPD and emphysema(69).  Recently, whole-
exome sequencing in African-Americans identified three rare loss-of-function variants in 
HAL that were associated with increased histidine levels and were inversely related to 
coronary heart disease risk in African-American and European-American populations. 
Thus, a functional HAL variant may decrease histidine levels and increase susceptibility 
to COPD and emphysema through its effects on oxidative stress.  
The region associated with Amerindian ancestry and FEV1 on chromosome 7 
contained a candidate variant (rs4133185) within the AGMO gene. This SNP, 
rs4133185, has large differences in ancestry-specific allele frequencies (~0.8 for 
Amerindian and ≤0.2 for European and African) and is associated with obstructive 
physiology, as measured by FEV1 (p=7.43x10-7). In the conditional analysis, rs4133185 
explains part but not all of the admixture signal. SNP rs4133185 may not be the causal 
variant and the presence of multiple SNPs within the LAI region may explain the 
residual signal.  A prior report showed an association of AGMO with FVC in a multi-
ethnic population(70). Future whole-genome sequencing studies are needed for better 
fine mapping of this region. 
The chromosome 11 locus (rs291231) associated with FEV1 among ever 
smokers nominally replicated in the meta-analysis across all cohorts with admixed 
populations of African ancestry. However, the direction of effect was discordant in some 
replication cohorts.  Different directions of associations may be due different patterns of 
LD with the causal variant between populations. The minor allele in rs291231 might be 
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protective in ever smokers as demonstrated by a per-allele increase in FEV1 of 57.28 
mL.  
The chromosome 18 locus associated with FEV1/FVC among never smokers 
contained multiple SNPs. The lead SNP (rs7228593) varies in MAF across different 
Hispanic/Latino ancestry groups in HCHS/SOL (0.02-0.16), is common in African 
populations (MAF=0.39) and is not polymorphic in European populations (MAF=0)(71) 
These variable allele frequencies and small sample size for replication may have 
contributed to lack of replication. Differing environmental exposures and LD may explain 
the observed genetic association of FEV1/FVC among never smokers in HCHS/SOL 
and lack of replication in independent cohorts of different ancestry backgrounds.  
In the COPD analysis, SNP rs7709630, a genotyped intron variant in PDZD2, 
was a single SNP association with COPD. This genomic region replicated for airflow 
obstruction in an independent population of European ancestry(23) suggesting a true 
association. Whereas the CDRT15P1 locus only contained imputed SNPs and did not 
replicate, thus reducing the probability that this is a true association with COPD.   
We hypothesize that novel loci did not replicate due to small sample size of the 
Hispanic/Latino replication cohorts along with differing environmental exposures, 
differing LD, and the complex racial admixture(2) that varies by different Hispanic/Latino 
ancestry groups.  Furthermore, the novel locus for FEV1/FVC in HAL and the 
chromosome 18 locus for FEV1/FVC among never smokers have marked differences in 
MAF between race and ethnic populations suggesting genetic diversity between races 
in these loci. The highest MAF for the lead SNPs in the HAL and in the chromosome 18 
locus were observed in African populations  (MAF = 0.005 and 0.38, respectively) 
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compared with virtually no variability in European populations for these loci 
(MAF=0)(63). The lack of variance of these loci in European populations limits the ability 
to replicate these loci as the vast majority of GWAS of lung function have been 
performed in studies of European ancestry.  Evidence for replication of the novel locus 
on chromosome 11 for FEV1 in ever smokers was stronger in the meta-analysis of 
cohorts with admixed populations that include African ancestry compared with the meta-
analysis of all cohorts (p=0.007 and p=0.04, respectively) supporting the need for 
additional studies on admixed populations to identify possible ethnicity- or race-specific 
variants that may elucidate novel pathways in the pathogenesis of COPD. 
The study has several potential limitations. This population-based cohort of 
diverse Hispanic/Latino participants is subject to population stratification. Multiple loci 
demonstrated varying MAF across Hispanic/Latino groups highlighting the complex 
racial admixture of Hispanic/Latino populations and raises the possibility of residual 
population stratification. However, we adjusted our analysis for PCs and our inflation 
factors ranged from 0.988 to 1.026 which indicates good control of population 
stratification with small inflation. The COPD analysis consisted of 363 and 5,253 
participants with and without COPD (respectively), which is a relatively small sample 
size for a GWAS. We optimized COPD phenotype by limiting the analysis to age greater 
than or equal to 45 and used post-bronchodilator spirometry measurements to define 
COPD. 
 In conclusion, we identified novel biologically plausible signals associated with 
clinically important pulmonary measures with evidence for replication in ZSWIM7, 
AGMO, and PDZD2; confirmed previous reports of association with FEV1/FVC in 
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KCNE2 and GPR126, and established that loci previously identified in European 
populations are generalizable in Hispanic/Latino populations. There is a paucity of 
genetic studies for lung function that include under-represented minority populations, 
such as Hispanic/Latino(2, 72) and African populations(14, 26, 73-75). Our findings 
emphasize the importance of including admixed and multi-racial populations when 
performing genetic studies of complex diseases and have the potential to advance our 
understanding of genetic risks for lung disease affecting Hispanic/Latino populations.  
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Figure 1 Regional Association Plots and Forest Plots of genome wide significant loci 
associated with FEV1 and FEV1/FVC meta-analyzed across all Hispanic/Latino ancestry 
groups. 
 
For each locus, we provide regional association plots with correlations between the 
reference SNP (the SNP with the lowest p-value) and other SNPs in the region.  The 
reference SNPs a purple diamond (genotyped SNP) or upside down triangle (imputed 
SNP). Other SNPs in the region are depicted as circles (genotyped SNPs) and “X”s 
(imputed SNPs) . The correlations (r2) are calculated from the group of interest and are 
indicated by the colors shown on the plot. For each locus, we also provide a forest plot 
comparing the SNP-trait association testing results across the Hispanic/Latino ancestry 
groups.  (a) Regional association plot for the FEV1 locus (lead SNP rs4791658) on 
chromosome 17. (b) Forrest Plot for the FEV1 locus (lead SNP rs4791658) on 
chromosome 17. (c) Regional association plot for the FEV1/FVC locus (lead SNP 
rs145174011) on chromosome 12. (d) Forrest Plot for the FEV1/FVC locus (lead SNP 
rs192375903) on chromosome 12. 
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Figure 2 Regional Association Plots and Forest Plots of genome wide significant loci 
associated with FEV1 and FEV1/FVC stratified by smoking status and meta-analyzed 
across all Hispanic/Latino Ancestry groups. 
 
For each locus, we provide regional association plots with correlations between the 
reference SNP (the SNP with the lowest p-value) and other SNPs in the region.  The 
reference SNPs a purple diamond (genotyped SNP) or upside down triangle (imputed 
SNP). Other SNPs in the region are depicted as circles (genotyped SNPs) and “X”s 
(imputed SNPs). The correlations (r2) are calculated from the group of interest and are 
indicated by the colors shown on the plot. For each locus, we also provide a forest plot 
comparing the SNP-trait association testing results across the Hispanic/Latino ancestry 
in smoking stratified group of interest.  (a) Regional association plot for the FEV1/FVC 
locus among never smokers (lead SNP rs7228593) on chromosome 18. (b) Forrest Plot 
for the FEV1/FVC locus among never smokers (lead SNP rs7228593) on chromosome 
18. (c) Regional association plot for the FEV1 locus among ever smokers (lead SNP 
rs291231) on chromosome 11. (d) Forrest Plot for the FEV1 locus among ever smokers 
(lead SNP rs291231) on chromosome 11. 
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Figure 3 Regional Association Plot and Forest Plot of candidate variant identified in 
local ancestry interval region associated with Amerindian ancestry and FEV1 meta-
analyzed across all Hispanic/Latino ancestry groups. 
 
For each locus, we provide regional association plots with correlations between the 
reference SNP (the SNP with the lowest p-value) and other SNPs in the region.  The 
reference SNPs a purple diamond (genotyped SNP) or upside-down triangle (imputed 
SNP). Other SNPs in the region are depicted as circles (genotyped SNPs) and “X”s 
(imputed SNPs) . The correlations (r2) are calculated from the group of interest and are 
indicated by the colors shown on the plot.  We also provide a forest plot comparing the 
SNP-trait association testing results across the Hispanic/Latino ancestry groups.  (a) 
Regional association plot for the FEV1 locus (lead SNP rs4133185) on chromosome 7. 
(b) Forrest Plot for the FEV1 locus (lead SNP rs4133185) on chromosome 7. 
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Figure 4 Amerindian Admixture Mapping Region on Chromosome 7 for FEV1 
 
The left panel provides the admixture mapping results as two lines with the blue line 
representing results from the primary analysis, the green line representing results from 
the conditional analysis and the association results in the same region are represented 
as circles. The genome-wide significant threshold for admixture mapping in HCHS/SOL 
data set is the horizontal grey dashed line. The blue and green lines and circles are 
given as –log(p-value,10) against genomic positions. The red-filled triangle corresponds 
to the SNP used in the conditional analysis (rs4133185). The right panel provides the 
ancestry-specific effect allele frequencies for the SNP used in the conditional analysis 
(rs4133185), as estimated by ASAFE applied on HCHS/SOL data set(46).  
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Table 1: Characteristics of Participants in HCHS/SOL Study 
 
 
 
Central 
American 
Cuban Dominican Mexican 
Puerto 
Rican 
South 
American 
Combined 
Number of participants 1,315 2,138 1,063 4,438 2,000 868 11,822 
Age (years) 44 ± 13 49 ± 13 45 ± 14 44 ± 14 48 ± 14 46 ± 13 46 ± 14 
Male Sex (%) 40 47 35 39 43 40 41 
Height (cm) 160 ± 9 164 ± 9 162 ± 9 161 ± 9 163 ± 9 161 ± 9 162 ± 9 
BMI (kg/m2) 30 ± 6 29 ± 6 29 ± 6 30 ± 6 31 ± 7 29 ± 5 30 ± 6 
Smoking (never) % 68 52 77 65 48 66 61 
Smoking (former) % 19 19 13 19 20 20 19 
Smoking (current) % 13 29 10 16 32 14 20 
Pack years of smoking* 
4.5 
(1.7 - 14) 
18.5 
(6 - 36) 
8.2 
(3.4 – 18.3) 
4.0 
(1.3 – 10.5) 
11.0 
(4 – 25.5) 
4.9 
(1.5 - 16) 
7.5 
(2.4 - 21) 
Pre-bronchodilator 
FEV1 (liters) 
2.88 ± 0.74 2.80 ± 0.81 2.70±0.75 2.97 ± 0.78 2.70 ± 0.83 2.95 ± 0.79 2.86 ± 0.80 
Pre-bronchodilator 
FEV1/FVC (%) 
81.5 ± 5.9 78.7 ± 8.3 81.8 ± 7.2 80.8 ± 6.1 79.3 ± 7.9 80.1 ± 6.5 80.3 ± 7 
COPD n (%)† 24 (1.8) 124 (5.8) 24 (2.3) 85 (1.9) 86 (4.3) 20 (2.3) 363 (3.1) 
Airflow Limitation n (%)‡ 60 (4.6) 260 (12.2) 62 (5.8) 207 (4.7) 216 (10.8) 49 (5.7) 854 (7.2) 
Data presented as mean ± standard deviation for continuous measures and percentage for binary 
measures  
Definition of abbreviations:  FEV1 = forced expiratory volume in one second, FEV1/FVC = ratio of forced 
expiratory volume in one second over forced vital capacity % 
* Pack years of smoking presented as median ± Inter Quartile Range (IQR) in former or current smokers 
† Chronic Obstructive Pulmonary Disease defined as post-bronchodilator FEV1/FVC ratio < 0.70 
‡ Defined as pre-bronchodilator FEV1/FVC ratio < 0.70
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Table 2: Genome wide significant loci associated with FEV1 and FEV1/FVC 
 
SNP rsID Trait 
Position Build 37 
Chr: basepair 
Gene /nearest 
Gene(s) 
(function) 
Effect 
allele 
EAF 
Genotyped or 
Imputed SNP 
oevar* N Beta SE P Value 
rs76656601 FEV1/FVC 6: 168428548 
KIF25 
(intron) 
G 0.996 Imputed 0.7 11822 4.70 0.77 1.31 x 10-9 
rs4791658 FEV1 17:15884792 
ZSWIM7† 
(intron) 
G 0.541 Imputed‡ 0.996 11822 33.35 5.70 4.99 x 10-9 
rs145174011 FEV1/FVC 12: 96378700  
HAL† 
(Intron) 
T 0.997 Imputed 0.98 11822 4.85 0.85 9.59 x 10-9 
rs28593428 FEV1/FVC 21: 35632170 KCNE2 C 0.902 Imputed 0.996 11821 0.80 0.14 1.45 x 10-8 
rs262113 FEV1/FVC 6: 142824950 GPR126 T 0.812 Imputed† 0.999 11822 - 0.57 0.10 2.83 x 10-8 
 
rs74444778 
 
FEV1/FVC 7: 42553708 
LOC105375250 
(intron) 
G 0.999 Imputed 0.914 11822 6.17 1.12 3.61 x 10-8 
rs115745680 FEV1 5: 154407079 
GEMIN5 
KIF4B 
A 0.997 Imputed 0.981 11822 313.24 57.32 4.63 x 10-8 
 
Definition of abbreviations:  SNP= single nucleotide polymorphism, FEV1/FVC= ratio of forced expiratory volume in one second over forced 
vital capacity, 
Chr = chromosome, nearest gene = the nearest genes on each side of the intergenic marker, EAF = effect allele frequency, oevar = 
observed / expected variance, N = sample size used in testing the given variant, Beta (FEV1) = per-allele change in FEV1 (mL), Beta 
(FEV1/FVC) = per-allele change in FEV1/FVC %, SE = standard error  
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Gene abbreviations: KIF25 = (kinesin family member 25), ZSWIM7 = (zinc finger, SWIM-type containing 7), HAL= (histidine ammonia-
lyase), GPR126= (G protein-coupled receptor 126), KCNE2 = (potassium channel, voltage gated subfamily E regulatory beta subunit 2), 
GEMNIN5= gem nuclear organelle associated protein 5, KIF4B= kinesin family member 4B  
Analyses were performed using data imputed to 1000 Genome phase 1 data and stratified by Hispanic/Latino ancestry group and were 
adjusted for age, age2, sex, height, height2, smoking status, pack-years, sampling weights, first 5 principal components, Hispanic/Latino 
ancestry groups, kinship and block unit. Within subgroup estimates were then meta-analyzed.  Previously unreported associations are in 
bold. Retrospectively, association analyses using genetic data imputed to 1000 Genome phase 3 imputation panel were performed in novel 
loci. 
 
* oevar is provided by MACH software as a measure of imputation quality;  
† Results for analyses using genetic data imputed to 1000 Genome phase 3 imputation panel 
  ‡ Genotyped SNP in locus 
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Table 3: Loci associated with FEV1 and FEV1/FVC ratio at genome-wide significance in analyses stratified by smoking status 
Ever Smokers 
SNP rsID Trait 
Position Build 37 
Chr: basepair 
Nearest Gene(s) 
Effect 
allele 
EAF 
Genotyped or 
imputed SNP 
oevar* N Beta SE P Value 
Indel 
(no rs#) 
FEV1 11: 86006803 
EED 
CCDC81 
GACA  Imputed† 1.017  56.95 10.09 1.66 x 10-8 
rs291231 FEV1 11: 86007090 
EED 
CCDC81 
G 0.341 Imputed† 0.999 4595 57.28 10.19 1.92 x 10-8 
rs9974878 FEV1/FVC 21: 35642446 KCNE2 G 0.887 Imputed† 0.994 4594 1.28 0.23 3.58 x 10-8 
Never Smokers 
SNP rsID Trait  Nearest Gene(s) 
Effect 
allele 
EAF 
Genotyped or 
imputed SNP 
oevar* N Beta  P Value 
rs116726860 FEV1/FVC 2: 155486042 
KCNJ3 
GALNT13 
T 0.992 Imputed 0.897 7227 3.49 0.60 6.04 x 10-9 
rs7228593 FEV1/FVC 18: 73575704 
SMIM21 
LOC339298 
G 0.948 Imputed† 0.997 7227 1.34 0.24 3.47 x 10-8 
 
Definition of abbreviations:  SNP= single nucleotide polymorphism, FEV1/FVC= ratio of forced expiratory volume in one second over forced 
vital capacity, 
Chr = chromosome, nearest gene = the nearest genes on each side of the intergenic marker, EAF = effect allele frequency, oevar = 
observed / expected variance, N = sample size used in testing the given variant, Beta (FEV1) = per-allele change in FEV1 (mL), Beta 
(FEV1/FVC) = per-allele change in FEV1/FVC %, SE = standard error, Indel = Indel mutation  
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Gene abbreviations: KCNJ3 = potassium voltage-gated channel subfamily J member 3, GALNT13 = polypeptide N-
acetylgalactosaminyltransferase 13, SMIM21 = small integral membrane protein 21, EED = genes embryonic ectoderm development, 
KCNE2 = (potassium channel, voltage gated subfamily E regulatory beta subunit 2), MROH2A = (maestro heat-like repeat family member 
2A) 
Analyses were stratified by Hispanic/Latino ancestry group and smoking status. Model adjusted for age, age2, sex, height, height2, smoking 
status, pack-years, sampling weights, first 5 principal components, Hispanic/Latino ancestry groups, kinship and block unit. Within 
subgroup estimates were then meta-analyzed.  Previously unreported associations are in bold.   
* oevar is provided by MACH software as a measure of imputation quality; it is a measure of imputation quality 
† Genotyped SNP in locus 
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